Takeaways From 15 Years of Biologics at ACR

Allison Shelley and John Rodriguez

October 16, 2018

Rheumatologists will track major advances in treatment over recent years and discuss the implications for future practice.


CHICAGO — Major advances in the treatment of rheumatoid arthritis — with new therapies, fresh treat-to-target strategies, and improved understanding of the window of opportunity — have transformed the practice of rheumatology.

In a presentation coming this weekend at the American College of Rheumatology (ACR) 2018 Annual Meeting, Spanish investigators will help quantify the extent to which newer agents are helping patients with rheumatoid arthritis maintain low disease activity or remission after starting a first biologic agent.

In spite of advances, "data from clinical practice confirming the benefits of using these strategies are scarce," explain investigators, led by Patricia Bogas, MD, from La Paz University in Madrid, in the background information about their upcoming presentation.

Medscape Medical News will be onsite to report on these 15-year trends and other hot topics from the conference, including nonmedical switches to biosimilars and an FDA safety update for rheumatic diseases.

Follow Medscape on Twitter @Medscape and Allison Shelley @allishelley



Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: